Abstract:Objectives: To explore the effect of escitalopram combined with aripiprazole on cognitive function in patients with major depressive disorder (MDD), and to evaluate the clinical efficacy of the combination therapy. Method: A total of 70 patients with first-episode MDD were randomly divided into the study group or the control group, receiving escitalopram combined with aripiprazole (5 mg/day) or escitalopram monotherapy respectively for 8 weeks. The severity of illness was assessed by using the Hamilton Rating Scale for Depression (HAMD) at baseline, at the end of 4th and 8th week, and cognitive function was assessed by using the THINC integrated tool (THINC-it), the Wisconsin Card Sorting Test (WCST), and the Continuous Performance Test (CPT). Rating Scale for Extrapyramidal Side Effects (RSESE) was applied to assess adverse reactions. Results: The average HAMD-17 and HAMA scores decreased over time in both the control and the study groups, but the reductions were not statistically different between two groups with the passage of time. In WCST, total number of response (TR) of the study group decreased relative to the baseline at the end of the eighth week, but the control group did not significantly change during whole eight weeks. Perseverative errors (PE) in the control group eventually decreased at the end of Week 8 compared to that at Week 4, but in the study group, it was a continuous trend of decrease. In CPT, the decrease of leakage responses (LR) in the study group was higher than that of the control group in 2-digit number, and LR of the control group was higher than that of the study group at the end of Week 8 in 4-digit number. The downtrend of LR in 4-digit number kept for the whole period in study group, while in the control group, the LR did not decrease significantly until the end of Week 8 compared to that at baseline. Conclusion: Escitalopram combined with a low-dose of aripiprazole, and escitalopram monotherapy could both enhance cognitive function of MDD patients, while the improvements of combination therapy might happen relatively earlier. The combined use of escitalopram and aripiprazole might be more beneficial to the domains of executive function (EF) and continuous attention compared to escitalopram monotherapy. There was no significant differences between two treatment options in alleviating depressive and anxiety symptoms.

Control study of mirtazapine and fluoxetine in therapy of depression

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

Consensus of mirtazapine in treatment of depression

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

A Preliminary Study of Different Treatment Strategies for Anxious Depression.

Efficacy of fluoxetine combined with psychological intervention for treatment of depressive patients with insomnia

Mirtazapine and Fluoxetine in the Treatment of Cardiovascular Neurosis with Depression

Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial

Efficacy of Escitalopram Monotherapy in the Treatment of Major Depressive Disorder

The efficacy and safety of trazodone plus fluoxetine in the treatment of male depression patients

Acute Changes of Polysomnography in Major Depressive Disorder Patients Treated with Mirtazapine

Repetitive Transcranial Magnetic Stimulation In Combination With Citalopram In Young Patients With First-Episode Major Depressive Disorder: A Double-Blind, Randomized, Sham-Controlled Trial

Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine

[Repetitive Transcranial Magnetic Stimulation Combined with Antidepressant Medication in Treatment of First-Episode Patients with Major Depression].

A study of antidepressant augmentation with mirtazapine in outpatients with major depression

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

A Control Study of Paroxetine Combined with Aripiprazoie in the Treatment of Depression.

Efficacy and Safety of Escitalopram in Treatment of Severe Depression in Chinese Population.

Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional connectivity analyses

Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial